Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
https://investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-and-etesevimab-together-reduced
Eli Lilly and Company
https://investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-and-etesevimab-together-reduced
Eli Lilly and Company
Mar 9th, 2021 - INDIANAPOLIS, March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together significantly reduced COVID-19 related hospitalizations and deaths ("events") in high-risk patients recently diagnosed with CO...
Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients
https://clinicaltrials.gov/ct2/show/NCT04718480
https://clinicaltrials.gov/ct2/show/NCT04718480
Jan 21st, 2021 - This is a randomized, double-blind, placebo-controlled, adaptive two-stage design, human phase 2 study, with add-on treatment arrangement of fluvoxamine or placebo on top of standard of care (base therapy: the actual proposed therapy of moderate SARS-CoV-2 infected patients according to "Hungarian Coronavirus Handbook", including antiviral and immunmodulant therapy and reconvalescent plasma the...
FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA
Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
FDA
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
FDA
Jun 14th, 2020 - On June 15, 2020, the Food and Drug Administration granted accelerated approval to lurbinectedin(ZEPZELCA, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
FDA approves nivolumab for esophageal squamous cell carcinoma
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma
FDA
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma
FDA
Jun 9th, 2020 - On June 10, 2020, the Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com
May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials
FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer
FDA
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer
FDA
May 5th, 2020 - On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA
Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia
FDA
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia
FDA
Apr 20th, 2020 - The Food and Drug Administration expanded the indication of ibrutinib (IMBRUVICA, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf
https://esperion.gcs-web.com/node/11206/pdf
Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiov...
Baudax Bio Announces FDA Approval of ANJESO™ for the Management of Moderate to Severe Pain
https://www.baudaxbio.com/news-and-investors/press-releases/detail/160/baudax-bio-announces-fda-approval-of-anjeso-for-the
https://www.baudaxbio.com/news-and-investors/press-releases/detail/160/baudax-bio-announces-fda-approval-of-anjeso-for-the
Feb 24th, 2020 - Baudax Bio, Inc., a pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ANJESO™ (meloxicam injection), which is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
https://www.prnewswire.com/news-releases/seqirus-receives-fda-approval-for-fluad-quadrivalent-influenza-vaccine-adjuvanted-for-adults-65-years-and-older-301009593.html
https://www.prnewswire.com/news-releases/seqirus-receives-fda-approval-for-fluad-quadrivalent-influenza-vaccine-adjuvanted-for-adults-65-years-and-older-301009593.html
Feb 24th, 2020 - Seqirus announced today that the U.S. Food and Drug Administration (FDA) has approved the first adjuvanted quadrivalent influenza vaccine, FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), to help protect adults 65 years and older against seasonal influenza.1
TAZVERIK™ (tazemetostat) - Official Website - Physicians
https://www.tazverik.com/
https://www.tazverik.com/
Jan 26th, 2020 - Introducing TAZVERIK™ 200 mg tablets. FDA-approved. Learn more about this new treatment. A new oral treatment. See full Prescribing Information. Patient Support Form · Product Access · Learn more tazemetostat epithelioid sarcoma
AYVAKIT™ (avapritinib) tablets | FDA Approved
https://www.ayvakit.com/hcp/
https://www.ayvakit.com/hcp/
Jan 14th, 2020 - AYVAKIT is a precision therapy option.
Official HCP Site - Now Approved ENHERTU®
https://www.enhertuhcp.com/
https://www.enhertuhcp.com/
Jan 14th, 2020 - Find Prescriber Information For Now Approved ENHERTU®. View PI & Boxed Warning. HCP Resources. Efficacy Data. Patient Guides. Savings & Support.
CAPLYTA® (lumateperone) | Now Approved | caplyta.com
https://www.caplyta.com/
https://www.caplyta.com/
Jan 13th, 2020 - Learn about a new treatment. See full safety information, PI, and boxed warning. Get information about this orally administered capsule. Press Release. Prescribing Information. MOA. Important Safety Info. Dosing & Administration.
FDA Approves Atezolizumab with Nab-paclitaxel & Carboplatin for Metastatic NSCLC Without EGFR/ALK Aberrations
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-nab-paclitaxel-and-carboplatin-metastatic-nsclc-without-egfralk
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-nab-paclitaxel-and-carboplatin-metastatic-nsclc-without-egfralk
Dec 2nd, 2019 - The Food and Drug Administration approved atezolizumab (TECENTRIQ, Genentech Inc.) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.
Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film
http://aquestive.com/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film/
http://aquestive.com/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film/
Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-action approval from the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS), an orphan disease.
The Best Guide to HIV Drug Names — Yours for Free!
https://blogs.jwatch.org/hiv-id-observations/index.php/the-best-guide-to-hiv-drug-names-yours-for-free/2019/11/18/?emp=marcom&utm_source=jwlist&utm_medium=email&utm_campaign=nov19&cid=DM79846&bid=120865710
Journal Watch;
https://blogs.jwatch.org/hiv-id-observations/index.php/the-best-guide-to-hiv-drug-names-yours-for-free/2019/11/18/?emp=marcom&utm_source=jwlist&utm_medium=email&utm_campaign=nov19&cid=DM79846&bid=120865710
Journal Watch;
Nov 20th, 2019 - HIV drug names
Commonly Abused Drugs Charts
https://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts
NIH
https://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs-charts
NIH
Nov 9th, 2019 - Many misused drugs can alter a person’s thinking and judgment, leading to health risks, including addiction, drugged driving and infectious disease. Most drugs could potentially harm an unborn baby; pregnancy-related issues are listed in the chart below for drugs where there is enough scientific evidence to connect the drug use to specific negative effects. Commonly Abused Drugs.
